341 related articles for article (PubMed ID: 28019637)
1. Recent Advances in Targeted Therapy for Glioma.
Lin L; Cai J; Jiang C
Curr Med Chem; 2017; 24(13):1365-1381. PubMed ID: 28019637
[TBL] [Abstract][Full Text] [Related]
2. Targeted molecular therapy of malignant gliomas.
Kesari S; Ramakrishna N; Sauvageot C; Stiles CD; Wen PY
Curr Neurol Neurosci Rep; 2005 May; 5(3):186-97. PubMed ID: 15865884
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
4. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy for malignant glioma based on PTEN status.
Gonzalez J; de Groot J
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1767-79. PubMed ID: 18983237
[TBL] [Abstract][Full Text] [Related]
6. The challenges and the promise of molecular targeted therapy in malignant gliomas.
Wang H; Xu T; Jiang Y; Xu H; Yan Y; Fu D; Chen J
Neoplasia; 2015 Mar; 17(3):239-55. PubMed ID: 25810009
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapies for malignant glioma.
Lukas RV; Boire A; Nicholas MK
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S29-36. PubMed ID: 18076315
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeting for malignant gliomas (Review).
Kondo Y; Hollingsworth EF; Kondo S
Int J Oncol; 2004 May; 24(5):1101-9. PubMed ID: 15067331
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies for malignant glioma: progress and potential.
Mercer RW; Tyler MA; Ulasov IV; Lesniak MS
BioDrugs; 2009; 23(1):25-35. PubMed ID: 19344189
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted therapy for malignant glioma.
Sathornsumetee S; Reardon DA; Desjardins A; Quinn JA; Vredenburgh JJ; Rich JN
Cancer; 2007 Jul; 110(1):13-24. PubMed ID: 17520692
[TBL] [Abstract][Full Text] [Related]
11. Current and future strategies for treatment of glioma.
Bush NA; Chang SM; Berger MS
Neurosurg Rev; 2017 Jan; 40(1):1-14. PubMed ID: 27085859
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis and invasion in glioma.
Onishi M; Ichikawa T; Kurozumi K; Date I
Brain Tumor Pathol; 2011 Feb; 28(1):13-24. PubMed ID: 21221826
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
14. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
[TBL] [Abstract][Full Text] [Related]
15. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
16. Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.
Carpenter CD; Alnahhas I; Gonzalez J; Giglio P; Puduvalli VK
Expert Rev Neurother; 2019 Jul; 19(7):663-677. PubMed ID: 31106606
[No Abstract] [Full Text] [Related]
17. Targeting malignant glioma survival signalling to improve clinical outcomes.
Wong ML; Kaye AH; Hovens CM
J Clin Neurosci; 2007 Apr; 14(4):301-8. PubMed ID: 17276069
[TBL] [Abstract][Full Text] [Related]
18. Glioma stem cell signaling: therapeutic opportunities and challenges.
Dietrich J; Diamond EL; Kesari S
Expert Rev Anticancer Ther; 2010 May; 10(5):709-22. PubMed ID: 20470003
[TBL] [Abstract][Full Text] [Related]
19. Emerging molecular therapies for brain tumors.
Van Meir EG; Bellail A; Phuphanich S
Semin Oncol; 2004 Apr; 31(2 Suppl 4):38-46. PubMed ID: 15124133
[TBL] [Abstract][Full Text] [Related]
20. Emerging targeted therapies for glioma.
Miller JJ; Wen PY
Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
